Reply to: "Methodological considerations when calculating person-time at risk for patients with chronic hepatitis C undergoing antiviral treatment"

Affiliations

¹ Humanitas University and IRCCS Istituto Clinico Humanitas, Rozzano, Italy. Electronic address: savino.bruno@hunimed.eu.
² Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy.

Comment

Savino Bruno et al. J Hepatol. 2017 Aug.

. 2017 Aug;67(2):428-429.

doi: 10.1016/j.jhep.2017.04.005. Epub 2017 Apr 21.

¹ Humanitas University and IRCCS Istituto Clinico Humanitas, Rozzano, Italy. Electronic address: savino.bruno@hunimed.eu.
² Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy.

No abstract available

Comment on

Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population.
Bruno S, Di Marco V, Iavarone M, Roffi L, Crosignani A, Calvaruso V, Aghemo A, Cabibbo G, Viganò M, Boccaccio V, Craxí A, Colombo M, Maisonneuve P. Bruno S, et al. J Hepatol. 2016 Jun;64(6):1217-23. doi: 10.1016/j.jhep.2016.01.034. Epub 2016 Apr 5. J Hepatol. 2016. PMID: 27059129
Methodological considerations when calculating person-time at risk for patients with chronic hepatitis C undergoing antiviral treatment.
Hallager S, Ladelund S, Weis N. Hallager S, et al. J Hepatol. 2017 Aug;67(2):427-428. doi: 10.1016/j.jhep.2017.02.035. Epub 2017 Apr 21. J Hepatol. 2017. PMID: 28435039 No abstract available.